Skip to main content
. 2023 Jan 5;3(1):20220045. doi: 10.1002/EXP.20220045

FIGURE 6.

FIGURE 6

MPS blockade approaches to reduce the MPS clearance and improve tumor delivery efficacy of NMs. (A) The injection dose of NMs determines their distribution and tumor delivery. Reproduced with permission.[ 117 ] Copyright 2020, Springer Nature. High doses of AuNPs reduce the accumulation in the liver (B) and increase tumor delivery (C) in xenogeneic U87 glioma‐bearing mice. Reproduced with permission.[ 115 ] Copyright 2020, Springer Nature. (D) Anti‐erythrocyte‐mediated erythrocytes clearance blocks the MPS and enhances the bioavailability of intravenously injected NMs. Reproduced with permission.[ 118 ] Copyright 2020, Springer Nature. (E) The circulation half‐lives of both short‐ and long‐circulating NMs with (test group, red) and without (control group, blue) MPS cytoblockade. Short‐circulating NMs: 200‐nm Estapor (Merck Millipore), 1‐μm Dynabeads MyOne (Thermo Fisher Scientific); long‐circulating NMs: 8 nm CdSe/ZnS quantum dots, 50‐ and 100‐nm fluidMAG‐ARA (Chemicell). Plot of tumor volume versus time after the treatment of doxorubicin‐loaded magnetic liposomes (F) or Caelyx (G) with and without 34‐3C‐induced MPS‐cytoblockade in B16‐F1 melanoma‐bearing mice. Reproduced with permission.[ 116 ] Copyright 2020, Springer Nature.